Zydus receives final USFDA approval for Prochlorperazine Maleate Tablets; Stock soars 2%

11 Aug 2022 , 12:31 PM

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) has announced that from the United States Food and Drug Administration (USFDA) it has received final approval to market Prochlorperazine Maleate tablets, USP 5 mg and 10 mg.

As per the filing, Prochlorperazine tablets are used to treat nervous, emotional, and mental conditions (eg. schizophrenia) and non-psychotic anxiety. It is also used to control severe nausea and vomiting problems. The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ in India.

 According to IQVIA MAT June 2022, Prochlorperazine Maleate tablets had annual sales of USD 30 million in the United States

The group now has 320 approvals and has so far filed over 428 ANDAs since the commencement of the filing process in FY 2003-04, the company said.

At around 12:31 PM, Zydus Lifesciences was trading at Rs372.80 per share up by Rs8.15 or 2.24% from its previous closing of Rs364.65 per share on the BSE.